Acacia Pharma starts first clinical trial with APD 405 for nausea & vomitting
Acacia Pharma has initiated its first clinical trial, a Phase I study of its lead product candidate APD 405. APD 405 is being developed for the prevention and treatment of nausea & vomiting, which remains a common problem after surgery and after treatment with many cancer chemotherapy drugs.
The clinical trial is a single ascending dose study of the safety, tolerability and pharmacokinetics of APD 405 in healthy volunteers. The trial will be exploring a range of six doses of APD 405 with six volunteers being enrolled at each dose level, one of whom will be randomised to receive a placebo.
APD 405 is an intravenous formulation of a drug that is already widely available in tablet form. Acacia has identified a new use for this drug, the prophylaxis and treatment of nausea & vomiting. The active ingredient within APD 405 hits two proven, complementary anti-emetic pathways. Acacia believes that this multifactorial approach could be of particular value in more difficult-to-treat patients, who often need more than one anti-emetic agent after surgery, or after highly emetogenic chemotherapy.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
